KRAS and neoplasm: In addition to BRCA2 biallelic loss-of-function and consistent with a diagnosis of PDNEC, the tumor harboured biallelic loss-of-function alterations affecting TP53 and RB1, a CDKN1B homozygous deletion, and a G12R KRAS hotspot mutation (Fig. 3).